Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

BACKGROUND: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS: In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once dai...

Descripción completa

Detalles Bibliográficos
Autores principales: Keystone, Edward C, Taylor, Peter C, Tanaka, Yoshiya, Gaich, Carol, DeLozier, Amy M, Dudek, Anna, Zamora, Jorge Velasco, Cobos, Jose Arturo Covarrubias, Rooney, Terence, de Bono, Stephanie, Arora, Vipin, Linetzky, Bruno, Weinblatt, Michael E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705852/
https://www.ncbi.nlm.nih.gov/pubmed/28798049
http://dx.doi.org/10.1136/annrheumdis-2017-211259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705852/
https://www.ncbi.nlm.nih.gov/pubmed/28798049
http://dx.doi.org/10.1136/annrheumdis-2017-211259

Ejemplares similares